TY - JOUR
T1 - Transcatheter aortic valve implantation versus surgical aortic valve replacement
T2 - a meta-analysis of randomized controlled trials
AU - Indraratna, Praveen
AU - Tian, David H.
AU - Yan, Tristan D.
AU - Doyle, Mathew P.
AU - Cao, Christopher
PY - 2016/12/1
Y1 - 2016/12/1
N2 - Background Transcatheter aortic valve implantation (TAVI) has become a widely utilized method of treatment of severe aortic valve stenosis. The present meta-analysis included all published relevant randomized controlled trials (RCTs) and aimed to compare the safety and efficacy of TAVI compared to surgical aortic valve replacement (AVR). Method Nine electronic databases were comprehensively searched. Eligible studies were required to be randomized controlled trials which reported comparative endpoints on both TAVI and AVR. Results Five published RCTs were included in the meta-analysis. A total of 3828 patients were studied. The overall mortality and stroke rates at 30 days and 1 year were not significantly different between TAVI and AVR. Patients undergoing TAVI were more likely to experience vascular complications, aortic regurgitation and permanent pacemaker insertion, however, they were less likely to encounter acute renal failure and major haemorrhage. Conclusions The data suggest that TAVI is a safe and efficacious alternative to surgical aortic valve replacement in judiciously selected patients.
AB - Background Transcatheter aortic valve implantation (TAVI) has become a widely utilized method of treatment of severe aortic valve stenosis. The present meta-analysis included all published relevant randomized controlled trials (RCTs) and aimed to compare the safety and efficacy of TAVI compared to surgical aortic valve replacement (AVR). Method Nine electronic databases were comprehensively searched. Eligible studies were required to be randomized controlled trials which reported comparative endpoints on both TAVI and AVR. Results Five published RCTs were included in the meta-analysis. A total of 3828 patients were studied. The overall mortality and stroke rates at 30 days and 1 year were not significantly different between TAVI and AVR. Patients undergoing TAVI were more likely to experience vascular complications, aortic regurgitation and permanent pacemaker insertion, however, they were less likely to encounter acute renal failure and major haemorrhage. Conclusions The data suggest that TAVI is a safe and efficacious alternative to surgical aortic valve replacement in judiciously selected patients.
UR - http://www.scopus.com/inward/record.url?scp=84988529635&partnerID=8YFLogxK
U2 - 10.1016/j.ijcard.2016.09.018
DO - 10.1016/j.ijcard.2016.09.018
M3 - Article
C2 - 27673695
AN - SCOPUS:84988529635
SN - 0167-5273
VL - 224
SP - 382
EP - 387
JO - International Journal of Cardiology
JF - International Journal of Cardiology
ER -